Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

stockholders$(8,220,785)$(9,768,246)Net Loss Per Share - Basic and Diluted$(0.38)$(1.30)Weighted Average Common Shares OutstandingBasic and diluted (include pre-funded warrants from the October 2025 offering)21,495,2747,492,460CITIUS PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSFOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024(Unaudited)20252024Cash Flows From Operating Activities:Net loss$(9,393,889)$(10,281,246)Adjustments to reconcile net loss to net cash used in operating acti ...